U.S. markets closed

Teva Pharmaceutical Industries Limited (TEVA.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
3,276.00-4.00 (-0.12%)
At close: 5:24PM IDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3,280.00
Bid4,401.00 x 200
Ask2,132.00 x 34100
Day's Range3,260.00 - 3,294.00
52 Week Range2,738.00 - 4,390.00
Avg. Volume1,490,457
Market Cap3.611T
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-3.57
Earnings DateOct 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 28, 2017
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA.TA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

      TEL AVIV, Israel & PARSIPPANY, N.J., October 21, 2021--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets. Study findings will be presented at the upcoming 2021 Psych Congress Annual


      The Most Exciting Medical Breakthrough Of The Decade?

      Artificial intelligence is coming for the $11 trillion doctor industry, and it could change how you and your doctor interact for decades to come

    • Business Wire

      New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

      AMSTERDAM, October 13, 2021--Teva Pharmaceuticals Europe BV, a European affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital – Katholisches Klinikum Bochum (Bochum, Germany), presented today at ECTRIMS congress new analyses of the COBRA study, a real-world evidence study on the safety of COPAXONE® (glatiramer acetate or GA) used by mothers with multiple sclerosis (MS) during pregnancy and breastfeeding.